|
AstraZeneca divests global rights to Movantik
|
25 February 2020 |
|
AstraZeneca divests rights to established hypertension medicines
|
27 January 2020 |
|
Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
|
20 January 2020 |
|
Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
|
15 January 2020 |
|
Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
|
06 January 2020 |
|
Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
|
31 December 2019 |
|
Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
|
18 December 2019 |
|
Agreement with Cheplapharm for rights to Seroquel and Seroquel XR in Europe and Russia completed
|
16 December 2019 |
|
Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
|
11 December 2019 |
|
AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada
|
03 December 2019 |